文献类型：期刊文献

英文题名：Epidermal Growth Factor-Ferritin H-Chain Protein Nanoparticles for Tumor Active Targeting

作者：Li, Xu[2];Qiu, Lihui[2];Zhu, Pei[2];Tao, Xinyi[2];Imanaka, Tadayuki[2];Zhao, Jing[3];Huang, Youguo[3];Tu, Yaping[1];Cao, Xuni[2]

机构：[1]Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA;[2]E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[3]Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China

年份：2012

卷号：8

期号：16

起止页码：2505

外文期刊名：SMALL

收录：;EI(收录号：20123315337402);WOS:【SCI-EXPANDED(收录号:WOS:000307390300009)】；

基金：This work was supported by the National Natural Science Foundation of China (Nos. 20805015, 21010102009), the State of Nebraska LB595 Research Program (USA), the Innovation Program of Shanghai Municipal Education Commission (No. 12ZZ048), Shanghai Committee of Science and Technology (11nm0505200, 10142200803, 11142200703, 11142201200), the Fundamental Research Funds for the Central Universities (ECUST No. WF0914025), and the National Special Fund for State Key Laboratory of Bioreactor Engineering (Grant No. 2060204).

语种：英文

外文关键词：Diseases - Tumors - Cytology - Controlled drug delivery - Proteins - Cells - Mammals - Safety factor - Targeted drug delivery - Cancer cells - Chains

摘要：Human ferritin H-chain protein (FTH1)-based nanoparticles possess a precisely assembled nanometer-scale structure and high safety. However, their applications for imaging and drug delivery towards cancer cells remain limited due to a lack of target specificity. Epidermal growth factor receptor (EGFR) is overexpressed in many malignant tissues including breast cancer, and has been used as a therapeutic target for cancer treatment. Herein, a genetic method is shown to generate EGF-FTH1 chimeric proteins. EGF-FTH1 nanoparticles with EGF on the surface are then produced. The data demonstrate that EGF-FTH1 nanoparticles, with a small size (11.8 mu 1.8 nm), narrow size distribution, and high biosafety, can specifically bind to and then be taken up by breast cancer MCF-7 cells and MDA-MB-231 cells, but not normal breast epithelial MCF-10A cells. In contrast, binding and absorption of nontargeted ferritin-based nanoparticles to breast cancer cells are negligible. In vivo studies show that EGF-FTH1 nanoparticles are accumulated in breast tumors in a mouse xenograft model. Interestingly, the concentration of EGF-FTH1 nanoparticles in the tumor site is significantly reduced when mice are pretreated with an excess of free EGF. These results imply that EGF-EGFR interaction plays an important role in regulating the tumor retention of EGF-FTH1 nanoparticles.